A secondary analysis of a phase 3 trial suggests that patients with relapse within 3 months of treatment or persistent disease represent a distinct high-risk group.
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kane: In talking ...
Molecular profiling and prognosis of spindle cell/sclerosing rhabdomyosarcoma: A report from the Chinese PPOG trial. A phase Ib/II trial of radiotherapy combined with doxorubicin and PD-1 antibody for ...
Changes in demographics and patterns of colon cancer in the United States: A comprehensive SEER analysis 2010–2021. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Relapse prevention is why most people seek treatment, and with opioid use disorders (OUDs), there’s about a 90 percent relapse rate. This article explains why and how specific sayings from self-help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results